Durable treatment response of relapsing CNS plasmacytoma using intrathecal chemotherapy, radiotherapy, and Daratumumab

CNS myelomatous involvement is a rare complication of multiple myeloma with dismal outcome. This disease's optimal treatment is unclear. Combined approach of systemic therapy, radiotherapy, and intrathecal injections chemotherapy should be considered and autologous stem cell transplant consolid...

Descripción completa

Detalles Bibliográficos
Autores principales: Elhassadi, Ezzat, Murphy, Maurice, Hacking, Dayle, Farrell, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5889271/
https://www.ncbi.nlm.nih.gov/pubmed/29636948
http://dx.doi.org/10.1002/ccr3.1451
_version_ 1783312675005005824
author Elhassadi, Ezzat
Murphy, Maurice
Hacking, Dayle
Farrell, Michael
author_facet Elhassadi, Ezzat
Murphy, Maurice
Hacking, Dayle
Farrell, Michael
author_sort Elhassadi, Ezzat
collection PubMed
description CNS myelomatous involvement is a rare complication of multiple myeloma with dismal outcome. This disease's optimal treatment is unclear. Combined approach of systemic therapy, radiotherapy, and intrathecal injections chemotherapy should be considered and autologous stem cell transplant consolidation is offered to eligible patients. The role of Daratumumab in this disease deserves further evaluation.
format Online
Article
Text
id pubmed-5889271
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-58892712018-04-10 Durable treatment response of relapsing CNS plasmacytoma using intrathecal chemotherapy, radiotherapy, and Daratumumab Elhassadi, Ezzat Murphy, Maurice Hacking, Dayle Farrell, Michael Clin Case Rep Case Reports CNS myelomatous involvement is a rare complication of multiple myeloma with dismal outcome. This disease's optimal treatment is unclear. Combined approach of systemic therapy, radiotherapy, and intrathecal injections chemotherapy should be considered and autologous stem cell transplant consolidation is offered to eligible patients. The role of Daratumumab in this disease deserves further evaluation. John Wiley and Sons Inc. 2018-03-02 /pmc/articles/PMC5889271/ /pubmed/29636948 http://dx.doi.org/10.1002/ccr3.1451 Text en © 2018 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Elhassadi, Ezzat
Murphy, Maurice
Hacking, Dayle
Farrell, Michael
Durable treatment response of relapsing CNS plasmacytoma using intrathecal chemotherapy, radiotherapy, and Daratumumab
title Durable treatment response of relapsing CNS plasmacytoma using intrathecal chemotherapy, radiotherapy, and Daratumumab
title_full Durable treatment response of relapsing CNS plasmacytoma using intrathecal chemotherapy, radiotherapy, and Daratumumab
title_fullStr Durable treatment response of relapsing CNS plasmacytoma using intrathecal chemotherapy, radiotherapy, and Daratumumab
title_full_unstemmed Durable treatment response of relapsing CNS plasmacytoma using intrathecal chemotherapy, radiotherapy, and Daratumumab
title_short Durable treatment response of relapsing CNS plasmacytoma using intrathecal chemotherapy, radiotherapy, and Daratumumab
title_sort durable treatment response of relapsing cns plasmacytoma using intrathecal chemotherapy, radiotherapy, and daratumumab
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5889271/
https://www.ncbi.nlm.nih.gov/pubmed/29636948
http://dx.doi.org/10.1002/ccr3.1451
work_keys_str_mv AT elhassadiezzat durabletreatmentresponseofrelapsingcnsplasmacytomausingintrathecalchemotherapyradiotherapyanddaratumumab
AT murphymaurice durabletreatmentresponseofrelapsingcnsplasmacytomausingintrathecalchemotherapyradiotherapyanddaratumumab
AT hackingdayle durabletreatmentresponseofrelapsingcnsplasmacytomausingintrathecalchemotherapyradiotherapyanddaratumumab
AT farrellmichael durabletreatmentresponseofrelapsingcnsplasmacytomausingintrathecalchemotherapyradiotherapyanddaratumumab

Ejemplares similares